Fig. 2
From: The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer
Molecular profiling by PTC-MA in 70 RAI-refractory and RAI-avid primary PTCs. a Percentage of cases harboring the different genetic alterations tested for each radioiodine (RAI) class (RAI+/D+, initial RAI uptake but disease persistence; RAI−/D+, without RAI uptake and disease persistence; and RAI+/D-, RAI uptake and disease remission). BRAFV600E was statistically significant more prevalent in RAI−/D+ compared with the other 2 classes (66% vs 35 and 33%, P = 0.032). b Clinical and molecular features of the patients included in the 3 different RAI classes. Note that some patients had the coexistence of 2 different mutations. Abbreviations: N, Lymph-Node involvement; ETE, Extrathyroidal Extension; MTS, Metastases; AJCC, American Joint Committee on Cancer